How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,541 results for

Ivermectin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Ivermectin for Parasitic Skin Infections of Lice: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Ivermectin for Parasitic Skin Infections of Lice: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Ivermectin for Parasitic Skin Infections of Lice: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Ivermectin for Parasitic Skin Infections of Lice: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Ivermectin for Parasitic Skin Infections of Lice: A Review (...) of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: May 14, 2019 Project Number: RC1115-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of oral versus topical ivermectin for parasitic skin infections of lice? What is the comparative clinical effectiveness of oral ivermectin versus pediculicides for parasitic skin infections of lice? What is the comparative

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Ivermectin for Parasitic Skin Infections (...) of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: May 16, 2019 Project Number: RC1116-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of oral versus topical ivermectin for parasitic skin infections of scabies? What is the comparative clinical effectiveness of oral ivermectin versus scabicides for parasitic skin infections of scabies

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Treatment of scabies: 5% permethrin cream or oral ivermectin?

Treatment of scabies: 5% permethrin cream or oral ivermectin? Prescrire IN ENGLISH - Spotlight ''Treatment of scabies. 5% permethrin cream or oral ivermectin?'', 1 June 2019 {1} {1} {1} | | > > > Treatment of scabies. 5% permethrin cream or oral ivermectin? Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the June issue of Prescrire (...) International - Treatment of scabies: 5% permethrin cream or oral ivermectin? FREE DOWNLOAD In patients with scabies, topical application of 5% permethrin cream and oral ivermectin have a similar harm-benefit balance. How do these two treatment options stack up? Full text available for free download. Summary According to a meta-analysis of six randomised trials, including a total of about 600 patients with scabies, 5% permethrin cream seems to be more rapidly effective than oral ivermectin. Two weeks after

2019 Prescrire

4. Ivermectin (Soolantra) by moderate to severe papulopustulous rosacea

Ivermectin (Soolantra) by moderate to severe papulopustulous rosacea Ivermectin (Soolantra®) by moderate to severe papulopustulous rosacea | Report | National Health Care Institute You are here: Ivermectin (Soolantra®) by moderate to severe papulopustulous rosacea Search within English part of National Health Care Institute Search Ivermectin (Soolantra®) by moderate to severe papulopustulous rosacea Zorginstituut Nederland advises the Minister of Public Health, Welfare and Sport to include (...) ivermectin (Soolantra®) in the GVS on list 1A, in cluster 0D06BXAD V. The applicable standard dose is 1 gram. Share this page Service About this site

2019 National Health Care Institute (Zorginstituut Nederland)

5. Soolantra (ivermectin) - inflammatory lesions of papulopustular rosacea

Soolantra (ivermectin) - inflammatory lesions of papulopustular rosacea Soolantra (ivermectin) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Soolantra (ivermectin) Conclusion Soolantra is a cream indicated for the topical treatment of inflammatory lesions of papulopustular rosacea in adult patients (>18 years). Soolantra contains ivermectin, which is a member of the avermectin class of anti-parasitic medications. The anti-parasitic effect (...) and ivermectin's anti-inflammatory properties are presumed to make up the mechanism of action in the treatment of papulopustular rosacea. The effect of Soolantra is well-established in a number of clinical trials, which showed that Soolantra had a superior effect in reducing the severity of rosacea (IGA success) as well as inflammatory lesions compared to both placebo and metronidazole 0.75% cream (Rozex). Efficacy onset is 3-4 weeks after treatment. Also, the patient-related improvement was assessed

2017 Danish Pharmacotherapy Reviews

6. Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for treatment of onchocerciasis - a randomized open-label clinical trial. Full Text available with Trip Pro

Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for treatment of onchocerciasis - a randomized open-label clinical trial. Improved treatment for onchocerciasis is needed to accelerate onchocerciasis elimination in Africa. Aiming to better exploit registered drugs, this study was undertaken to determine whether annual or semiannual treatment with ivermectin (IVM; 200µg/kg) plus albendazole (ALB; 800mg single dose) is superior to IVM alone.This trial was performed

2019 Clinical Infectious Diseases

7. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40 mg modified-release capsules versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. Full Text available with Trip Pro

A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40 mg modified-release capsules versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. Randomized controlled studies of combination therapies in rosacea are limited.Evaluate efficacy and safety of combining ivermectin 1% cream (IVM) and doxycycline 40 mg modified-release capsules∗ (DMR) versus IVM and placebo (PBO) for treatment of severe rosacea.This 12-week

2019 Journal of American Academy of Dermatology Controlled trial quality: uncertain

8. Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream

Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream Inflammatory lesions of papulopustular rosacea: Inflammatory lesions of papulopustular rosacea: iv ivermectin 10 mg/g cream ermectin 10 mg/g cream Evidence summary Published: 19 January 2016 nice.org.uk/guidance/esnm68 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in January 2016. See summaries of product characteristics (SPCs), British national (...) formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary In 2 randomised controlled trials (RCTs) ivermectin cream was statistically significantly more effective than vehicle cream (placebo) in improving rosacea severity score and reducing inflammatory lesion count. In another RCT, ivermectin was superior to metronidazole cream at reducing lesion count and improving rosacea severity score. Local adverse events, including skin burning sensation, skin irritation, pruritus and dry

2016 National Institute for Health and Clinical Excellence - Advice

9. Ivermectin (Soolantra) - topical treatment of inflammatory lesions of rosacea (papulopustular)

Ivermectin (Soolantra) - topical treatment of inflammatory lesions of rosacea (papulopustular) Final Appraisal Recommendation Advice No: 0216 – February 2016 Ivermectin (Soolantra ® ) 10 mg/g cream Submission by Galderma Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1627), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR (...) Recommendation 0216: Ivermectin (Soolantra ® ) 10 mg/g cream. February 2016. Recommendation of AWMSG Ivermectin (Soolantra ® ) is recommended as an option for use within NHS Wales for the topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients.

2016 All Wales Medicines Strategy Group

10. Difficult-to-treat scabies: oral ivermectin

Difficult-to-treat scabies: oral ivermectin Difficult-to-treat scabies: or Difficult-to-treat scabies: oral iv al ivermectin ermectin Evidence summary Published: 18 March 2014 nice.org.uk/guidance/esuom29 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2014. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date (...) information. Summary Oral ivermectin appears to be effective for treating people with classical or crusted scabies. However, differences in treatment regimens and the length of follow-up make interpreting comparisons with topical treatments difficult. Transient exacerbation of pruritus may occur at the beginning of treatment. Regulatory status: Regulatory status: unlicensed The topic was prioritised because there was a high volume of requests from the NHS for information on this topic

2014 National Institute for Health and Clinical Excellence - Advice

11. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Full Text available with Trip Pro

Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Ivermectin is widely used in mass drug administrations for controlling neglected parasitic diseases, and can be lethal to malaria vectors that bite treated humans. Therefore, it could be a new tool to reduce plasmodium transmission. We tested the hypothesis that frequently repeated mass administrations of ivermectin to village residents would reduce clinical (...) malaria episodes in children and would be well tolerated with minimal harms.We invited villages (clusters) in Burkina Faso to participate in a single-blind (outcomes assessor), parallel-assignment, two-arm, cluster-randomised trial over the 2015 rainy season. Villages were assigned (1:1) by random draw to either the intervention group or the control group. In both groups, all eligible participants who consented to the treatment and were at least 90 cm in height received single oral doses of ivermectin

2019 Lancet Controlled trial quality: predicted high

12. Adherence to ivermectin is more associated with perceptions of community directed treatment with ivermectin organization than with onchocerciasis beliefs Full Text available with Trip Pro

Adherence to ivermectin is more associated with perceptions of community directed treatment with ivermectin organization than with onchocerciasis beliefs The fight against onchocerciasis in Africa has boomed thanks to the Community Directed Treatment with Ivermectin (CDTI) program. However, in Cameroon, after more than 15 years of mass treatment, onchocerciasis prevalence is still above the non-transmission threshold. This study aimed to explore a possible association between people's beliefs (...) /perceptions of onchocerciasis and of CDTI program, and their adherence to ivermectin in three regions of Cameroon.A cross sectional survey was carried out in three health districts with persistent high onchocerciasis prevalence. Participants were randomly selected in 30 clusters per district. Adherence to ivermectin was comparable between Bafang and Bafia (55.0% and 48.8%, respectively, p>0.05) and lower in Yabassi (40.7%). Among all factors related to program perceptions and disease representations

2017 PLoS neglected tropical diseases

13. Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil

Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil (...) Ltda, Brazil) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference

2017 Clinical Trials

14. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Full Text available with Trip Pro

Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. The morbidity and socioeconomic effects of onchocerciasis, a parasitic disease that is primarily endemic in sub-Saharan Africa, have motivated large morbidity and transmission control programmes. Annual community-directed ivermectin treatment has substantially reduced prevalence. Elimination requires (...) by sex and level of infection, to receive a single oral dose of 8 mg moxidectin or 150 μg/kg ivermectin as overencapsulated oral tablets. The primary efficacy outcome was skin microfilariae density 12 months post treatment. We used a mixed-effects model to test the hypothesis that the primary efficacy outcome in the moxidectin group was 50% or less than that in the ivermectin group. The primary efficacy analysis population were all participants who received the study drug and completed 12-month

2018 Lancet Controlled trial quality: predicted high

15. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. (Abstract)

Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. Ivermectin is a potential new vector control tool to reduce malaria transmission. Mosquitoes feeding on a bloodmeal containing ivermectin have a reduced lifespan, meaning they are less likely to live long enough to complete sporogony and become infectious. We aimed to estimate the effect of ivermectin on malaria transmission in various scenarios of use.We validated an existing (...) population-level mathematical model of the effect of ivermectin mass drug administration (MDA) on the mosquito population and malaria transmission against two datasets: clinical data from a cluster- randomised trial done in Burkina Faso in 2015 wherein ivermectin was given to individuals taller than 90 cm and entomological data from a study of mosquito outcomes after ivermectin MDA for onchocerciasis or lymphatic filariasis in Burkina Faso, Senegal, and Liberia between 2008 and 2013. We extended

2020 Lancet infectious diseases

16. Dominance of P-glycoprotein 12 in phenotypic resistance conversion against ivermectin in Caenorhabditis elegans. Full Text available with Trip Pro

Dominance of P-glycoprotein 12 in phenotypic resistance conversion against ivermectin in Caenorhabditis elegans. While diseases caused by nematodes remains a considerable drawback for the livestock, agriculture and public health, anthelmintics drug resistance has been observed over the past years and is a major concern for parasite control. Ivermectin, initially considered as a highly potent drug, currently presents a reduced anti-helminthic efficacy, which is influenced by expression (...) of several ATP-binding cassette transporters (ABC), among them the P-glycoproteins (Pgps). Here we present some evidences of Pgps dominance during Ivermectin resistance/susceptibility using Pgps double silencing in C. elegans and the phylogenetic relationship of Pgps among nematodes, which strengthen the use of this model for study of drug resistance in nematodes. Firstly, we evaluated the quantitative gene expression of 12 out the 15 known Pgps from resistant and WT strains of C. elegans, we

2018 PLoS ONE

17. Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System Full Text available with Trip Pro

Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System The mainstay of onchocerciasis control currently is mass administration of ivermectin; however, this may be associated with serious adverse events, including deaths, when administered in areas where onchocerciasis and loiasis are co-endemic.The objective of the current study was to describe the central and peripheral (...) nervous system disorders that occurred after mass administration of ivermectin in Democratic Republic of Congo (DRC).This is a retrospective descriptive study involving a review of data on adverse events related to mass administration of ivermectin. Data on reported serious adverse events following mass administration of ivermectin in the DRC were extracted from the World Health Organization (WHO) Global individual case safety report (ICSR) database (VigiBase). The review covered the period 2009-2013

2017 Drugs - real world outcomes

18. Systematic review with meta analysis: Treatment for chronic Strongyloides stercoralis infection: moderate-to-low evidence shows that ivermectin is more effective and tolerable than albendazole and thiabendazole, respectively

Systematic review with meta analysis: Treatment for chronic Strongyloides stercoralis infection: moderate-to-low evidence shows that ivermectin is more effective and tolerable than albendazole and thiabendazole, respectively Treatment for chronic Strongyloides stercoralis infection: moderate-to-low evidence shows that ivermectin is more effective and tolerable than albendazole and thiabendazole, respectively | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our (...) or password? You are here Treatment for chronic Strongyloides stercoralis infection: moderate-to-low evidence shows that ivermectin is more effective and tolerable than albendazole and thiabendazole, respectively Article Text Therapeutics/Prevention Systematic review with meta analysis Treatment for chronic Strongyloides stercoralis infection: moderate-to-low evidence shows that ivermectin is more effective and tolerable than albendazole and thiabendazole, respectively Dora Buonfrate , Federico Gobbi

2016 Evidence-Based Medicine

19. Investigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogs. (Abstract)

Investigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogs. The purpose of this study was to determine the pharmacokinetic interaction between ivermectin (0.4 mg/kg) and praziquantel (10 mg/kg) administered either alone or co-administered to dogs after oral treatment. Twelve healthy cross-bred dogs (weighing 18-21 kg, aged 1-3 years) were allocated randomly into two groups of six dogs (four females, two males) each. In first group (...) , the tablet forms of praziquantel and ivermectin were administered using a crossover design with a 15-day washout period, respectively. Second group received tablet form of ivermectin plus praziquantel. The plasma concentrations of ivermectin and praziquantel were determined by high-performance liquid chromatography using a fluorescence and ultraviolet detector, respectively. The pharmacokinetic parameters of ivermectin following oral alone-administration were as follows: elimination half-life (t1/2λz

2019 Journal of veterinary pharmacology and therapeutics Controlled trial quality: uncertain

20. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. Full Text available with Trip Pro

Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. In small community-based trials, mass drug administration of ivermectin has been shown to substantially decrease the prevalence of both scabies and secondary impetigo; however, their effect at large scale is untested. Additionally, combined mass administration of drugs for two or more neglected diseases has potential (...) practical advantages, but efficacy of potential combinations should be confirmed.The azithromycin ivermectin mass drug administration (AIM) trial was a prospective, single-arm, before-and-after, community intervention study to assess the efficacy of mass drug administration of ivermectin for scabies and impetigo, with coadministration of azithromycin for trachoma. Mass drug administration was offered to the entire population of Choiseul Province, Solomon Islands, and of this population we randomly

2019 Lancet infectious diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>